chlordiazepoxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 594 58-25-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlordiazepoxide
  • chlordiazepoxide hydrochloride
  • chloridazepoxide
  • methaminodiazepoxide
  • chlordiazepoxid
  • chlorodiazepoxide
  • chlordiazepoxide HCl
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
  • Molecular weight: 299.76
  • Formula: C16H14ClN3O
  • CLOGP: 3.79
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 53.14
  • ALOGS: -4.18
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 14.30 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.25 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.37 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.30 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.646 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.998 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 55.590 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 14.689 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 4.670 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 10.710 % High 1
herg hERG pIC50 4.922 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.466 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 5.808 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 2.650 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 47
kinase-selectivity-class AXL,GRK2,TTK 3
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.155 High 1
mh-clint Mouse hepatocyte intrinsic clearance 132.434 High 1
mppb Mouse plasma protein binding (% unbound) 5.180 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 7.178 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 10.190 % High 1
rh-clint Rat hepatocyte intrinsic clearance 29.580 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 51.210 % High 1
rppb Rat plasma protein binding (% unbound) 3.600 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 55.081 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 24, 1960 FDA VALEANT PHARM INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral venous thrombosis 224.81 23.07 43 3288 2285 90622831
Drug abuse 137.96 23.07 65 3266 82282 90542834
Bradyphrenia 96.77 23.07 27 3304 7585 90617531
Hyperreflexia 95.66 23.07 26 3305 6631 90618485
Toxicity to various agents 87.08 23.07 77 3254 287769 90337347
Drug interaction 85.72 23.07 75 3256 276378 90348738
Thalamic infarction 85.27 23.07 15 3316 497 90624619
Completed suicide 76.72 23.07 54 3277 145004 90480112
Sopor 62.28 23.07 26 3305 24618 90600498
Disorientation 56.37 23.07 29 3302 44085 90581031
Drug withdrawal syndrome 52.11 23.07 24 3307 28699 90596417
Intentional product misuse 51.17 23.07 35 3296 89569 90535547
Clonus 49.18 23.07 15 3316 5735 90619381
Apraxia 47.77 23.07 12 3319 2250 90622866
Perseveration 45.13 23.07 8 3323 277 90624839
Dyskinesia 43.75 23.07 23 3308 36511 90588605
Slow response to stimuli 39.73 23.07 9 3322 1087 90624029
Overdose 35.68 23.07 36 3295 157673 90467443
Muscle twitching 34.08 23.07 17 3314 24185 90600931
Generalised tonic-clonic seizure 33.54 23.07 19 3312 34884 90590232
Derailment 33.01 23.07 5 3326 63 90625053
Abnormal behaviour 32.18 23.07 16 3315 22612 90602504
Brain stem syndrome 32.04 23.07 7 3324 717 90624399
Abdominal tenderness 31.03 23.07 12 3319 9312 90615804
Disturbance in attention 30.72 23.07 20 3311 47089 90578027
Withdrawal syndrome 29.31 23.07 15 3316 22509 90602607
Renal tubular necrosis 29.04 23.07 13 3318 14542 90610574
Confusional state 28.63 23.07 51 3280 386154 90238962
Myoclonus 28.58 23.07 14 3317 19154 90605962
Psychomotor retardation 26.60 23.07 9 3322 4780 90620336
Cognitive disorder 25.87 23.07 21 3310 69386 90555730
Drug dependence 25.60 23.07 15 3316 29312 90595804
Cardiogenic shock 25.36 23.07 14 3317 24454 90600662
Areflexia 24.84 23.07 8 3323 3645 90621471
Serotonin syndrome 24.49 23.07 16 3315 37871 90587245
Body temperature increased 24.40 23.07 17 3314 44693 90580423
Accidental overdose 23.47 23.07 14 3317 28259 90596857
Cardio-respiratory arrest 23.31 23.07 19 3312 63121 90561995

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 233.44 29.58 116 2383 104655 42514181
Toxicity to various agents 200.07 29.58 138 2361 228998 42389838
Ventricular tachyarrhythmia 101.00 29.58 18 2481 397 42618439
Dystonic tremor 83.43 29.58 15 2484 348 42618488
Delirium 71.13 29.58 42 2457 52477 42566359
Delusion of replacement 63.02 29.58 11 2488 214 42618622
Overdose 50.88 29.58 45 2454 105219 42513617
Completed suicide 44.14 29.58 40 2459 96425 42522411
Restlessness 43.81 29.58 25 2474 29224 42589612
Shoshin beriberi 43.75 29.58 7 2492 78 42618758
Withdrawal syndrome 43.73 29.58 20 2479 14755 42604081
Dystonia 30.73 29.58 15 2484 12775 42606061

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 368.56 23.32 175 5028 177236 110406860
Toxicity to various agents 231.19 23.32 186 5017 480369 110103727
Cerebral venous thrombosis 199.66 23.32 43 5160 3219 110580877
Completed suicide 114.23 23.32 93 5110 242288 110341808
Drug interaction 98.29 23.32 119 5084 500064 110084032
Dystonic tremor 92.92 23.32 16 5187 361 110583735
Hyperreflexia 84.29 23.32 27 5176 9458 110574638
Bradyphrenia 78.66 23.32 27 5176 11701 110572395
Delirium 76.88 23.32 58 5145 134967 110449129
Sopor 75.33 23.32 36 5167 36510 110547586
Intentional product misuse 68.89 23.32 54 5149 132850 110451246
Thalamic infarction 67.03 23.32 15 5188 1337 110582759
Disorientation 65.46 23.32 41 5162 70630 110513466
Delusion of replacement 63.19 23.32 11 5192 265 110583831
Drug withdrawal syndrome 62.14 23.32 32 5171 38022 110546074
Overdose 61.76 23.32 65 5138 233729 110350367
Withdrawal syndrome 58.90 23.32 29 5174 31351 110552745
Cardio-respiratory arrest 47.31 23.32 41 5162 115795 110468301
Shoshin beriberi 45.28 23.32 7 5196 78 110584018
Alcoholism 43.24 23.32 13 5190 3694 110580402
Respiratory arrest 42.20 23.32 29 5174 58270 110525826
Perseveration 39.92 23.32 8 5195 419 110583677
Abnormal behaviour 39.57 23.32 24 5179 39015 110545081
Apraxia 39.51 23.32 12 5191 3528 110580568
Clonus 39.42 23.32 15 5188 8701 110575395
Abdominal tenderness 37.52 23.32 16 5187 12441 110571655
Agoraphobia 35.80 23.32 8 5195 708 110583388
Slow response to stimuli 32.20 23.32 9 5194 1979 110582117
Dyskinesia 31.25 23.32 23 5180 51423 110532673
Confusional state 30.84 23.32 68 5135 468612 110115484
Derailment 30.72 23.32 5 5198 79 110584017
Coma 29.70 23.32 32 5171 117837 110466259
Muscle twitching 29.30 23.32 18 5185 29917 110554179
Dementia 28.36 23.32 18 5185 31655 110552441
Speech disorder 27.59 23.32 23 5180 61546 110522550
Drug dependence 27.35 23.32 21 5182 49999 110534097
Restlessness 27.27 23.32 22 5181 56237 110527859
Poisoning 27.21 23.32 17 5186 29088 110555008
Accidental overdose 26.69 23.32 21 5182 51813 110532283
Dystonia 26.49 23.32 16 5187 25789 110558307
Brain stem syndrome 26.04 23.32 7 5196 1332 110582764
Tracheobronchitis 25.23 23.32 8 5195 2708 110581388

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BA02 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:60807 anaesthesia adjuvant
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
FDA EPC N0000175694 Benzodiazepine

Related Drugs by ATC class:

N05BA Benzodiazepine derivatives 23 drugs
adinazolamalprazolambentazepambromazepamcamazepamclobazamclorazepateclotiazepamcloxazolamdiazepamethyl loflazepateetizolam show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alcohol withdrawal delirium indication 8635005
Irritable bowel syndrome indication 10743008 DOID:9778
Peptic ulcer indication 13200003 DOID:750
Anxiety indication 48694002
General anesthesia indication 50697003
Severe anxiety (panic) indication 80583007
Alcohol withdrawal syndrome indication 191480000
Mixed anxiety and depressive disorder indication 231504006
Local anesthesia indication 386761002
Preoperative Anxiety indication
Pre-Op Apprehension indication
Anxiety associated with Menopause indication
Panic disorder off-label use 371631005 DOID:594
Tension-type headache off-label use 398057008
Brain damage contraindication 2470005
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Hypocalcemia contraindication 5291005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Sinus tachycardia contraindication 11092001
Hypercholesterolemia contraindication 13644009
Severe chronic ulcerative colitis contraindication 14311001
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Orthostatic hypotension contraindication 28651003
Atony of colon contraindication 29479008
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Body fluid retention contraindication 43498006
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Thrombophlebitis contraindication 64156001 DOID:3875
Ulcerative colitis contraindication 64766004 DOID:8577
Intermenstrual bleeding - irregular contraindication 64996003
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Chronic idiopathic constipation contraindication 82934008
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Uterine leiomyoma contraindication 95315005 DOID:13223
Prolonged QT interval contraindication 111975006
Hypoalbuminemia contraindication 119247004
Gastrointestinal obstruction contraindication 126765001
Deep venous thrombosis contraindication 128053003
Endometriosis contraindication 129103003
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Mammography abnormal contraindication 168750009
Bipolar affective disorder, current episode manic contraindication 191618007
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Myocardial dysfunction contraindication 233928007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Syncope contraindication 271594007
Chorea contraindication 271700006
Drowsy contraindication 271782001
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Severe chronic obstructive pulmonary disease contraindication 313299006
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Myocardial infarction in recovery phase contraindication 418044006
Porphyria contraindication 418470004
Family history of malignant neoplasm of breast contraindication 429740004
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.79 Basic
pKa2 4.13 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-2/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 6.34 WOMBAT-PK CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 6.56 WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 6.50 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 6.25 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel Ki 6.25 CHEMBL
Cholecystokinin receptor GPCR IC50 4 CHEMBL
Histamine H1 receptor GPCR Ki 6.68 DRUG MATRIX
Thyrotropin-releasing hormone receptor GPCR Ki 6.54 WOMBAT-PK
Thyrotropin-releasing hormone receptor GPCR ANTAGONIST Ki 4.82 IUPHAR
Cholinesterase Enzyme Ki 6.52 CHEMBL
Thyrotropin-releasing hormone receptor GPCR ANTAGONIST Ki 4.70 IUPHAR
GABA-A receptor; anion channel Ion channel IC50 6.70 CHEMBL
GABA-A receptor; anion channel Ion channel IC50 6.10 CHEMBL
Cholecystokinin receptor GPCR IC50 4 CHEMBL
Acetylcholinesterase Enzyme Ki 4.30 CHEMBL
Translocator protein Membrane receptor Ki 6.36 CHEMBL

External reference:

IDSource
4017780 VUID
N0000146141 NUI
D00267 KEGG_DRUG
438-41-5 SECONDARY_CAS_RN
203173 RXNORM
C0008188 UMLSCUI
CHEBI:3611 CHEBI
CHEMBL451 ChEMBL_ID
CHEMBL1200703 ChEMBL_ID
DB00475 DRUGBANK_ID
D002707 MESH_DESCRIPTOR_UI
2712 PUBCHEM_CID
3370 IUPHAR_LIGAND_ID
1049 INN_ID
6RZ6XEZ3CR UNII
3903 MMSL
4409 MMSL
4410 MMSL
d00189 MMSL
001454 NDDF
001455 NDDF
372866006 SNOMEDCT_US
40601003 SNOMEDCT_US
82746003 SNOMEDCT_US
4017780 VANDF
4017808 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Librax HUMAN PRESCRIPTION DRUG LABEL 2 0187-4100 CAPSULE 5 mg ORAL NDA 16 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 0276-0500 CAPSULE 5 mg ORAL ANDA 19 sections
Chlordiazepoxide and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0211 TABLET, FILM COATED 5 mg ORAL ANDA 24 sections
Chlordiazepoxide and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0277 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0555-0033 CAPSULE 10 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0555-0158 CAPSULE 5 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0555-0159 CAPSULE 25 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 10135-622 CAPSULE 5 mg ORAL UNAPPROVED DRUG OTHER 17 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 11534-197 CAPSULE 5 mg ORAL ANDA 19 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0164 CAPSULE 25 mg ORAL ANDA 19 sections
Chlordiazepoxide and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 42571-302 TABLET 12.50 mg ORAL ANDA 23 sections
Chlordiazepoxide and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 42571-303 TABLET 25 mg ORAL ANDA 23 sections
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE HUMAN PRESCRIPTION DRUG LABEL 2 42571-381 CAPSULE 5 mg ORAL ANDA 21 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 42582-300 CAPSULE 5 mg ORAL UNAPPROVED DRUG OTHER 18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 42582-301 CAPSULE 5 mg ORAL UNAPPROVED DRUG OTHER 18 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-562 CAPSULE, GELATIN COATED 10 mg ORAL ANDA 21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-563 CAPSULE, GELATIN COATED 25 mg ORAL ANDA 21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-564 CAPSULE, GELATIN COATED 5 mg ORAL ANDA 21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-565 CAPSULE, GELATIN COATED 10 mg ORAL ANDA 21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42806-566 CAPSULE, GELATIN COATED 25 mg ORAL ANDA 21 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-046 CAPSULE 25 mg ORAL ANDA 17 sections
Chlordiazepoxide hydrochloride and clidinium bromide Human Prescription Drug Label 2 46708-744 CAPSULE 5 mg ORAL ANDA 24 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-019 CAPSULE 10 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 48433-020 CAPSULE 25 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride/Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 50090-0131 CAPSULE 5 mg ORAL Unapproved drug other 19 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-0328 CAPSULE 25 mg ORAL ANDA 19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide HUMAN PRESCRIPTION DRUG LABEL 2 50090-1528 CAPSULE 5 mg ORAL NDA authorized generic 18 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-141 CAPSULE 25 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-141 CAPSULE 25 mg ORAL ANDA 17 sections
Chlordiazepoxide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-374 CAPSULE 5 mg ORAL ANDA 17 sections